June 2014

What is CPI? CPI (Continuous Process Improvement) is the CIBMTR quality assurance program that monitors forms submission for US allogeneic HCTs. It includes both TED and Comprehensive Report Forms. To meet CPI goals, a transplant center must submit at least 90% of the forms due within that trimester.


The CPI reports are generated in January, May and September. If a center meets CPI, their status is "Good Standing". If the center does not meet CPI, their status is "First Warning". If they continue not to meet CPI, the center will have the status of "Probation Warning", then "Probation" and finally "Suspension".


The CPI program has been extremely successful due to all your hard work. Usually, over 90% of the US centers meet CPI goals each trimester. Meeting the forms submission goals supports the SCTOD reporting requirements, Transplant Center Specific Analysis (TCSA), Center Volumes, BMT-CTN, RCI-BMT and Observational Studies.


Your contributions directly impact the advancement of stem cell transplant and improved patient outcomes.



Thank you,

CIBMTR Data Operations

CIBMTR® is a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin.



No Data Management Manual updates to report for April.
Link to (PDF):

2400:  Pre-TED

2000: Recipient Baseline

2100: 100 Days Post-HCT Data

2200: Six Months to Two Years Post-HCT

2014:  MDS/MPN Pre-HCT Data

2116: Plasma Cell Disorders (PCD)

We are pleased to see the increased use of ScanForm as it helps with quality control.

Reporting Cause of Death

Finding the correct answers to report for a transplant recipient's cause of death might involve a little detective work. Reviewing the autopsy report and communicating with the transplant team to review the chain of events that led to the patient's death will determine what to report as the primary cause of death and contributing causes.


Here are a few tips for reporting causes of death:

  • The cause of death must occur before actual death.
  • Persistent disease, cytogenetic or molecular evidence of disease may not be the primary or only explanation as a cause of death.
  • Think through the chain or sequence of events that led to death.

The goal is to track back to the root cause. Try to identify which event(s) is/are a consequence and which event is/may be an underlying cause. An example would be that the patient died of cardiac arrest. What caused the cardiac arrest? Was the heart damaged from the preparative regimen? Did the patient have septicemia? Another example is, if the patient died of GVHD, the CRFs or post-TED form should report the patient had GVHD and that it was 'still occurring at time of last report'. Also, the severity of the GVHD should be reviewed. If the GVHD is mild, then most likely cause of death was not GVHD and another cause of death should be reported.

The resource for death codes is found on pages 4 through 9 of the Form 2900 Instruction Manual.


To print or save: Cause of Death Codes (PDF)


Request for Recipient Transfer FORM 2801 Reformatted


CIBMTR is pleased to announce layout changes to provide clarity and increase form useability on the Request for Recipient Transfer Form 2801 and its matching Error Correction Form. Both forms were reformatted to more closely resemble the PDF-RF version of the forms released last Fall.   Fields to capture the printed names of the center's data managers were also added under the signature line. Note: This message is a repeat of the eBlast sent 5/22/2014.











If a patient had AML and developed Sweet's Syndrome, should that be reported on the Pre-TED as a comorbidity?



No, Sweet Syndrome would not be reported anywhere on the Pre-TED as it is associated with AML.



What if the patient has MDS that transformed to AML, should the MDS be reported as a comorbidity?



No, MDS is also a disease process of AML, so it is not considered a comorbidity. 



Comorbid conditions that should be reported on the Pre-TED are diseases or organ impairments, that the patient is currently under treatment for at the time of HCT, or, are of a severity to potentially threaten the patient's ability to endure the transplant and crucial recovery time, such as: 

  • Diabetes (do not report if treated with diet alone)
  • Renal insufficiency on dialysis, or with a creatinine>2.0 mg/dL
  • Hepatitis B & C (should be reported as "hepatic, mild" comorbidity, even if not under treatment at the time of HCT.
  • TB; and HIV (should be reported as an "infection" comorbidity).
  • A subarachnoid hemorrhage (not subdural hemorrhage) or stroke at any time in a patient's history should be reported as a "cerebrovascular" comorbidity.

While, in contrast, these conditions in a patient's history would not qualify as comorbities: GERD, DVT, Pulmonary emboli, MRSA, epilepsy, Cerebral Palsy, Hepatitis A, psoriasis, and EBV.


The above mentioned conditions are examples, you can access more information through this reference: Appendix U from the Data Management Manual on our website www.cibmtr.org.


Send your questions into CIBMTRTraining@nmdp.org . The answer may be in a future newsletter.
Thank you to the contributors for this month's newsletter:
Marie Matlack, Senior Manager, Data Management; Janet Brunner-Grady, Program Director; Emilie Love, CRC III; Shirley Wayne, CRC ; and Lori Colt, Training Specialist.
CIBMTR Training